October 31, 2019 09:36 AM EDT

Thermo Fisher hooks gut onto its gene therapy pipeline, inks new collaboration pact

Jason Mast

Editor

Seven months ago, Thermo Fisher spent $1.7 billion to add a gene therapy company to its sprawling biotech business, purchasing Brammer Bio. Now they’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Thermo Fisher hooks gut onto its gene therapy pipeline, inks new collaboration pact

Jason Mast

Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

FDA approves Ionis’ treatment for a rare metabolic disorder

Sofinnova outlines $550M fund after IPOs and M&A deals

Ther­mo Fish­er hooks gut on­to its gene ther­a­py pipeline, inks new col­lab­o­ra­tion pact

Jason Mast

Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Thermo Fisher hooks gut onto its gene therapy pipeline, inks new collaboration pact

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

FDA approves Ionis’ treatment for a rare metabolic disorder

Sofinnova outlines $550M fund after IPOs and M&A deals